MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI): restructuring charge — Maravai Q2 revenue down 32% to $47.4M; net loss $69.8M; restructuring cuts 25% of workforce

MARAVAI LIFESCIENCES HOLDINGS, INC.

2025-Q2 EPS reported -$0.48 revenue$94,247,000

Q2 revenue $47.4M (-32% YoY); net loss $69.8M (incl. $30.4M goodwill impairment); adjusted EBITDA -$10.4M vs +$13.0M.
Announced restructuring targeting >$50M annualized savings; workforce reduction of ~25% with $8-9M severance costs.
Withdrew 2025 revenue guidance pending new leadership's business review.
CEO Bernd Brust recently appointed; EVP CCO Rebecca Buzzeo and EVP CAO Pete Leddy departing.
Base business revenue (ex high-volume CleanCap) grew 5% YoY; positive free cash flow expected by H2 2026.

item 2.02 item 2.05 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

MARAVAI LIFESCIENCES HOLDINGS, INC. announced a restructuring with charges of $8.0 million to $9.0 million affecting the Company's workforce (approximately 25% of the Company's workforce).

Type: restructuring
Charge: $8.0 million to $9.0 million
Affected area: the Company's workforce
Headcount: approximately 25% of the Company's workforce

Exact text from the filing

On August 11, 2025, the Company announced an organizational restructuring, including a workforce reduction, to reduce operating costs. The workforce reduction, which is being implemented as part of a strategic cost-reduction initiative, was committed to by management on August 8, 2025 and is expected to impact approximately 25% of the Company’s workforce. In connection with the workforce reduction, the Company currently estimates it will incur restructuring and related costs in the range of $8.0 million to $9.0 million, consisting primarily of employee severance and benefits costs, the majority of which the Company expects to recognize in the second half of 2025.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

MARAVAI LIFESCIENCES HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001823239-25-000105

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.